Modeling tumor–host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy

Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies

(2012) A. Agathangelidis et al.   BLOOD

Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia

(2012) A. Wiestner   BLOOD

The B-cell receptor signaling pathway as a therapeutic target in CLL

(2012) J. A. Woyach et al.   BLOOD

The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia

(2012) M. F. M. de Rooij et al.   BLOOD

Novel Targeted Agents and the Need to Refine Clinical End Points in Chronic Lymphocytic Leukemia

(2012) Bruce D. Cheson et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting B-Cell Receptor Signaling for Anticancer Therapy: The Bruton's Tyrosine Kinase Inhibitor Ibrutinib Induces Impressive Responses in B-Cell Malignancies

(2012) Adrian Wiestner   JOURNAL OF CLINICAL ONCOLOGY

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

(2012) Ranjana H. Advani et al.   JOURNAL OF CLINICAL ONCOLOGY

Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling

(2012) Marcus Dühren-von Minden et al.   NATURE

NOVEL AGENTS AND EMERGING STRATEGIES FOR TARGETING THE B-CELL RECEPTOR PATHWAY IN CLL

(2012) Dimitar Efremov et al.   Mediterranean Journal of Hematology and Infectious Diseases

A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease

(2011) D. Bagnara et al.   BLOOD

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765

(2011) S. E. M. Herman et al.   BLOOD

The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo

(2011) S. Ponader et al.   BLOOD

Investigating the role of CD38 and functionally related molecular risk factors in the CLL NOD/SCID xenograft model

(2011) Semra Aydin et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells

(2011) Betty Y Chang et al.   ARTHRITIS RESEARCH & THERAPY

Nurture versus Nature: The Microenvironment in Chronic Lymphocytic Leukemia

(2011) J. A. Burger   Hematology-American Society of Hematology Education Program

The lymph node microenvironment promotes B-cell receptor signaling, NF- B activation, and tumor proliferation in chronic lymphocytic leukemia

(2010) Y. Herishanu et al.   BLOOD

The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the E - TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling

(2010) M. Suljagic et al.   BLOOD

Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia

(2010) M. Buchner et al.   BLOOD

The DLEU2/miR-15a/16-1 Cluster Controls B Cell Proliferation and Its Deletion Leads to Chronic Lymphocytic Leukemia

(2010) Ulf Klein et al.   CANCER CELL

Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia ("accelerated" chronic lymphocytic leukemia) with aggressive clinical behavior

(2010) E. Gine et al.   HAEMATOLOGICA

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

(2010) L. A. Honigberg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Antigens in chronic lymphocytic leukemia—Implications for cell origin and leukemogenesis

(2010) Anders Rosén et al.   SEMINARS IN CANCER BIOLOGY

A novel Rag2-/- c-/--xenograft model of human CLL

(2009) M. T. S. Bertilaccio et al.   BLOOD

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

(2009) J. W. Friedberg et al.   BLOOD

Chronic lymphocytic leukemia microenvironment: shifting the balance from apoptosis to proliferation

(2009) S. Deaglio et al.   HAEMATOLOGICA

The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells

(2008) M. Luqman et al.   BLOOD

Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA

(2008) C. C. Chu et al.   BLOOD

Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy

(2008) M. Muzio et al.   BLOOD

Expression and function of toll like receptors in chronic lymphocytic leukaemia cells

(2008) Marta Muzio et al.   BRITISH JOURNAL OF HAEMATOLOGY

Microenvironmental influences in chronic lymphocytic leukaemia: the role of antigen stimulation

(2008) P. Ghia et al.   JOURNAL OF INTERNAL MEDICINE

The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells

(2007) P. G. Longo et al.   BLOOD